Genome Editing Market Is Anticipated To Presence Of Strong Pipeline Products Till 2025: Grand View Research, Inc.

The global genome editing market is anticipated to reach USD 8.1 billion by 2025, according to a new report by Grand View Research, Inc. Key drivers attributing to the expansion include early applications of DNA editing to therapeutics. Use of the technology for the disease eradication through direct correction of disturbances in normal physiology, engineering the immune response, and alteration of pathogen targets in the host is anticipated to drive the market with substantial opportunities.

The ability of genome editing therapies to offer a significant improvement over current treatment options is important in enabling editing technologies to capture significant revenue share. Improved efficacy, reduced side effects, and the potential for cure for specific diseases, can be attributed to induce growth in the coming years. 

Moreover, technological advancements with respect to the development of novel vectors for delivery is anticipated to fuel growth in the coming years. Rising competition amongst the operating entities in order to gain the larger share of revenue is also responsible for the projected growth. These companies leverage industry collaborations for the acceleration of diversified product pipelines. 

UK genome editing market, by end-use, 2014 - 2025 (USD Million)




Browse full research report on Genome Editing Market

Further key findings from the report suggest:

  • There has been great excitement surrounding the highly adaptable CRISPR technology.
  • The increased ease of retargeting and the ability to multiplex goes a long way toward explaining the speed with which CRISPR-centric companies have sprung up.
  • Ex-vivo mode of delivery accounted for the largest share of the revenue.
  • Therapy through ex-vivo mode of delivery allow the control over the specific dosage of therapeutic molecules delivered to cells.
  • Cell line engineering dominated with respect to revenue generation owing to the high utilization of technology in stem cell engineering.
  • There is comparatively, higher adoption of the technology in the biotechnology and pharmaceutical organizations for the purpose of therapeutic development.
  • Availability of other services such as gRNA library production and screening service along with editing is anticipated to propel growth in the outsourcing services.
  • Asia Pacific is anticipated to witness fastest growth over the forecast period owing to rising penetration of technology in comparatively immature market.
  • Key players contributing in this market are Thermo Fisher Scientific, Inc., Sangamo, Editas Medicine, Recombinetics, Inc, Sigma Aldrich Corporation, CRISPR THERAPEUTICS, Intellia Therapeutics, Inc., Caribou Biosciences, Inc.
  • These participants are capitalizing on unique advantages offered by the nuclease technology, they are working on.

 For more information: http://www.grandviewresearch.com

Comments

Popular posts from this blog

The global vein illuminator market is expected to reach USD 358.5 million by 2024, according to a new report published by Grand View Research, Inc. The vein illuminator market is anticipated to witness a lucrative growth during the period 2016 to 2024. The factors contributing towards the growth of the market are the growing aging population and the efforts channelized towards improving patient satisfaction. Additionally, factors, such as the demand for technologically advanced medical equipment and the rising research and practical applications are expected to be opportunistic for the industry growth. However, the prevalence of traditional methods owing to the high costs of the vein illuminator devices is likely to hinder the growth of the market in the near future. The vein illuminator market is segmented on the basis of technology, application, end-user, and region. Based on technology, the market is further categorized into transillumination, infrared technology, and ultrasound. The near-infrared illumination technology is estimated to be the largest shareholder due to its ability to penetrate deep into the tissue, which makes it possible to visualize the vessels clearly. On the basis of application, the market is segmented into intravenous access and blood draw. The end-user segment comprises hospitals, rehabilitation facilities, blood donation camps, and academic institutions. The market for hospitals is expected to grow rapidly during the forecast period due to a surge in the demand for technologically advanced medical equipment. The market is also categorized into North America, Europe, Asia Pacific, MEA, and Latin America. Browse full research report on global Vein Illuminator Market: http://www.grandviewresearch.com/industry-analysis/vein-illuminator-market Further key findings from the study suggest: • In terms of market share, the North America vein illuminator market is expected to hold majority of the share in 2016. Factors resulting in the growth of this industry are the steady preference for highly-advanced medical devices by hospitals as well as the presence of several medical device manufacturing companies in the region. • The infrared illumination technology is estimated to lead the industry due to its deep penetration capability into thick tissues tohighlight the presence of vessels with increased clarity. Based on application, the segment for intravenous access is estimated to be the largest shareholder, followed by the blood draw segment. • The vein illuminator industry comprises several local as well as global players. Some prominent players in this industry include Accuvein, Inc., Christie Medical Holdings, Inc., Infrared Imaging Systems, Inc., Translite, LLC, and Venoscope, LLC,among others. In order to hold a major share in the industry, the companies are adopting both organic as well as inorganic strategies. The major strategies adopted by the companies are new product development, mergers, collaborations, partnerships, geographical expansions, and acquisitions. • The companies are also focusing on research and development activities in order to enhance their product portfolio. For instance, in September 2015, Accuvein, Inc., declared its 26th patent, which was issued by the United States Patent and Trademark office for their vein visualization system. Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/medical-devices Grand View Research has segmented the vein illuminator market on the basis of technology, application, and end-user application: Vein Illuminator Technology Outlook (Revenue, USD Million, 2013 - 2024) • Transillumination • Infrared technology • Others Vein Illuminator Application Outlook (Revenue, USD Million, 2013 - 2024) • Intravenous access • Blood draw • Others Vein Illuminator End-user Outlook (Revenue, USD Million, 2013 - 2024) • Hospitals • Blood donation camps • Academic institutions • Others Vein Illuminator Regional Outlook (Revenue, USD Million, 2013 - 2024) • North America • Europe • Asia Pacific • Latin America • MEA Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-vein-illuminator-market About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare. Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc For more information: www.grandviewresearch.com

Hyaluronic Acid Market Is Likely To Be Influenced By The Increase In Obesity Till 2024: Grand View Research, Inc.

Protein Purification & Isolation Market Is Predicted To Grow Swiftly Due To Increased Research In The Fields Of Biotechnology & Pharmaceuticals Till 2025: Grand View Research, Inc.